People · Operator
Named in public records as an officer, director or promoter · active 2009–2023 · Biotechnology, Other, Other Energy, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Alliqua BioMedical, Inc. | — | Biotechnology | Series A | $52.6M | $100.1M | 2010 |
| Nexgel, Inc. | — | Biotechnology | Seed | $4.6M | $37.6M | 2009 |
| Celsia Technologies, Inc. | — | Other | Seed | $2.7M | $31.8M | — |
| Amber Kinetics, Inc. | — | Other Energy | Seed | $2.2M | $28.6M | 2015 |
| chatAND Inc | — | Other Technology | Pre-Seed | $1.1M | $11.2M | 2014 |
| Vicapsys Life Sciences, Inc. | — | Biotechnology | Pre-Seed | $800K | $2.9M | 2023 |
Richard Rosenblum at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Richard Rosenblum on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Berger | 2 | 7 |
| Jerome Zeldis | 2 | 6 |
| Kenneth Londoner | 2 | 5 |
| David Stefansky | 2 | 3 |
| David Johnson | 1 | 35 |
| Mark Wagner | 1 | 9 |
| David Rosenberg | 1 | 8 |
| James Sapirstein | 1 | 7 |
| Thomas Higgins | 1 | 5 |
| David Berger | 1 | 5 |
| Colleen Delaney | 1 | 4 |
| Gary Restani | 1 | 3 |
| Robert P. Grammen | 1 | 3 |
| Brian Posner | 1 | 3 |
| Joseph Sierchio | 1 | 3 |
| Adam Levy | 1 | 3 |
| Peter Rugg | 1 | 2 |
| Charles Resnick | 1 | 2 |
| Stephen Chiao | 1 | 2 |
| Perry Karsen | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.